中国药物评价2023，Vol.40Issue(6)：498-501,4.
国产创新钾离子竞争性酸阻滞剂在酸相关疾病中的应用价值
Application Value of Domestic Innovative Potassium-competitive Acid Blocker in Acid-related Diseases
摘要
Abstract
Acid-related diseases(ARDs)are common in the digestive department with characteristics of long course and frequent relapse,causing symptoms of heartburn and acid reflux which can adversely affect the patients'daily activities,work efficiency,and quality of life.Acid suppression is the key to ARDs treatment,including weakly alkaline drugs,H2 receptor antagonist,and the most commonly used proton pump inhibitor.Subsequently,the advent of potassium-competitive acid blocker(P-CAB)achieves a faster,longer-lasting,and stabler acid-suppressing effect.Until the current time,there are already multiple P-CABs for ARDs on the market worldwide.Tegoprazan,China's first independently developed P-CAB,not only provide a new selection for ARDs patients,but also has a great significance for new drug research and development in China.This article combed the value of domestic innovative P-CAB in acid-related diseases based on the evidence-based medical proof of tegoprazan,providing references for clinical medication in ARDs and benefiting more patients.关键词
酸相关疾病/胃食管反流病/反流性食管炎/钾离子竞争性酸阻滞剂/替戈拉生Key words
Acid-related diseases/Gastroesophageal reflux disease/Reflux esophagitis/Potassium-competitive acid blocker/Tego-prazan分类
医药卫生引用本文复制引用
孟宇,赵梦蕊,赵琨,隋忠国,王进..国产创新钾离子竞争性酸阻滞剂在酸相关疾病中的应用价值[J].中国药物评价,2023,40(6):498-501,4.基金项目
国家"重大新药创制"科技重大专项资助项目(项目编号:2020ZX09101013 （）
项目名称:新型钾离子竞争性酸阻滞剂(P-CAB)药物LXI-15028的临床研究) （P-CAB）
